Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

RAS

8 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

Cowzer D, Walch H, Atri P, et al.

Clinical cancer research

This study analyzed a cohort of 1,254 patients with biliary tract cancer to assess the utility of targeted NGS molecular profiling. It revealed that 59% of patients harbored at least one OncoKB alteration, and 32.2% had level 1/2 alterations, with varying frequencies across tumor locations. Targeted therapies were associated with improved progression-free survival but not overall survival. The study also identified co-occurring alterations and acquired resistance mechanisms, such as ERBB2 loss or alterations in the RAS, MEK, MET, MYC, and CDKN2A pathways. These findings highlight genomic heterogeneity and the importance of precision medicine in informing future drug development efforts.

Clinical

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer

Arbour KC, Punekar S, Luo J, et al.

The New England journal of medicine

This phase 1-2 study investigated the safety and efficacy of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated advanced RAS-mutant non-small-cell lung cancer (NSCLC). Patients received daily oral doses ranging from 10 to 400 mg. Results indicated that 99% of patients experienced adverse events of any grade, and 54% had grade 3 or higher events, with common side effects including rash and diarrhea. Antitumor activity, assessed by objective response rate, was over 30% across the evaluated dose groups.

Clinical · Molecular biology

Utility of RNA Sequencing and Immunohistochemistry for NTRK Fusion in Thyroid Carcinoma

Toda S, Kasajima R, Okubo Y, et al.

Anticancer research

This study evaluated the utility of RNA sequencing and immunohistochemistry (IHC) for detecting NTRK fusions in thyroid carcinoma, particularly those potentially missed by gene panel testing. Two patient groups were analyzed: advanced thyroid cancer cases undergoing panel testing and surgical papillary thyroid carcinoma cases screened by IHC. Results indicated that a gene panel test missed one SQSTM1-NTRK3 fusion, while pan-TRK IHC showed variable sensitivity depending on the fusion type. The study concludes that active screening for NTRK fusions is desirable, especially in patients without MAPK pathway abnormalities or with positive pan-TRK staining.

Clinical · Bioinfo & AI

Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer

Manca P, Walch H, Xu J, et al.

Cancer cell

This study performed an integrated clinicogenomic analysis on over 7,000 colorectal cancer (CRC) samples to characterize its genetic drivers and metastatic tropisms. Researchers found that genomic evolutionary changes, such as clonal mutations and oncogenic mutant allelic imbalance, enhance the impact of recurrent oncogenic alterations. The study identified the relative timing of organ-specific metastasis, showing sequential progression in microsatellite stable CRC, with brain and adrenal metastases as late events. It also revealed clustering of metastatic sites and genomic events that modify metastasis risk, with WNT pathway activation being protective and RAS pathway activation increasing the risk of widespread metastasis. These data suggest that integrating information about primary tumor location and genomics can predict organ-specific metastasis risk.

Clinical · Molecular biology

Small-molecule RAS/RAF inhibitors target RAS-driven cancers via allosteric RAF disruption

Yoshikawa Y, Kubota H, Matsumoto S, et al.

Nature communications

This study focuses on developing novel inhibitors targeting the RAS/RAF pathway, a significant challenge in oncology given the frequency of RAS mutations and acquired resistance to existing treatments. Researchers identified small molecules that covalently bind to a distinct site within the RAS-binding domain of RAF, leading to allosteric disruption of its conformation. This mechanism prevents RAS/RAF interaction and downstream signaling. These compounds demonstrated preclinical antitumor efficacy against various cancers with KRAS, NRAS, and HRAS mutations, as well as wild-type RAS-driven cancers. They also suppressed tumor growth in BRAFV600E melanoma with acquired BRAF inhibitor resistance by preventing RAS signal reactivation.

Clinical

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

O'Reilly EM, Wainberg ZA, Hendifar AE, et al.

The New England journal of medicine

This phase 3 study evaluated the efficacy and safety of daraxonrasib, a multiselective RAS(ON) inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Patients were randomized to receive either daraxonrasib or investigator’s choice chemotherapy. Results demonstrated significantly longer overall survival and progression-free survival with daraxonrasib compared to chemotherapy, both in the RAS G12 mutated population and the overall population. Daraxonrasib also showed a favorable safety profile, with a significantly lower rate of treatment discontinuation due to adverse events compared to chemotherapy.

Molecular biology

Utility of Urinary Extracellular Vesicles for Colorectal Cancer: Comparison of DNA Quality and MRD Detection

Kanaka S, Yamada T, Asai F, et al.

Cancer science

This study investigated the utility of urinary extracellular vesicles (EVs) as a liquid biopsy source for colorectal cancer (CRC). Urinary EVs demonstrated superior purity and DNA quality compared to plasma and urinary cell-free samples. Detecting RAS/BRAF mutations in urinary EV-DNA after curative surgery allowed for minimal residual disease (MRD) identification. MRD positivity was strongly associated with an increased risk of recurrence and inferior overall survival. These findings suggest that urinary EV-DNA is a promising tool for postoperative monitoring and risk stratification in CRC patients.

Clinical · Molecular biology

Clinical utility of longitudinal circulating tumor DNA analysis in metastatic colorectal cancer patients receiving palliative chemotherapy

Oh CR, Lee JY, Kim JE, et al.

Clinical & translational oncology

This prospective observational study assessed the utility of circulating tumor DNA (ctDNA) for mutational profiling and dynamic monitoring in 33 patients with metastatic colorectal cancer receiving palliative chemotherapy. ctDNA was detected in most patients at baseline, revealing frequent mutations in APC, TP53, KRAS, and PIK3CA. Good concordance was observed between plasma ctDNA profiles and tissue data. Longitudinal analysis showed the emergence of acquired mutations, particularly RAS mutations under anti-EGFR therapy, and correlated high ctDNA levels with shorter overall survival. These findings highlight ctDNA’s potential to guide personalized treatment strategies and monitor resistance.